| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
|
Rydzewska, Larysa H.M.
|
|
2017
|
84 |
C |
p. 88-101
14 p.
|
artikel
|
| 2 |
Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study
|
de Nonneville, A.
|
|
2017
|
84 |
C |
p. 34-43
10 p.
|
artikel
|
| 3 |
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
|
Li, Fang
|
|
2017
|
84 |
C |
p. 184-192
9 p.
|
artikel
|
| 4 |
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)
|
Sun, Roger
|
|
2017
|
84 |
C |
p. 202-211
10 p.
|
artikel
|
| 5 |
Breast cancer in young women and prognosis: How important are proliferation markers?
|
Fredholm, Hanna
|
|
2017
|
84 |
C |
p. 278-289
12 p.
|
artikel
|
| 6 |
Corrigendum to “Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification” [Eur J Cancer 78 (2017) 82–90]
|
Eggink, F.A.
|
|
2017
|
84 |
C |
p. 370-
1 p.
|
artikel
|
| 7 |
Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland
|
Tang, Sarah Shuk-Kay
|
|
2017
|
84 |
C |
p. 315-324
10 p.
|
artikel
|
| 8 |
Diagnostic characteristics of lethal prostate cancer
|
Helgstrand, John Thomas
|
|
2017
|
84 |
C |
p. 18-26
9 p.
|
artikel
|
| 9 |
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
|
Modest, D.P.
|
|
2017
|
84 |
C |
p. 262-269
8 p.
|
artikel
|
| 10 |
First-line treatment in metastatic colorectal cancer: Important or crucial?
|
Malka, David
|
|
2017
|
84 |
C |
p. 363-366
4 p.
|
artikel
|
| 11 |
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer
|
Bascoul-Mollevi, C.
|
|
2017
|
84 |
C |
p. 239-249
11 p.
|
artikel
|
| 12 |
High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine
|
Grellety, T.
|
|
2017
|
84 |
C |
p. 250-256
7 p.
|
artikel
|
| 13 |
Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study
|
Vermeulen, Ravi F.M.
|
|
2017
|
84 |
C |
p. 159-167
9 p.
|
artikel
|
| 14 |
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
|
Nebot-Bral, Laetitia
|
|
2017
|
84 |
C |
p. 290-303
14 p.
|
artikel
|
| 15 |
Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area
|
Schreuder, K.
|
|
2017
|
84 |
C |
p. 270-277
8 p.
|
artikel
|
| 16 |
Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK
|
Cufari, Maria Elena
|
|
2017
|
84 |
C |
p. 55-59
5 p.
|
artikel
|
| 17 |
Interlaboratory variability of Ki67 staining in breast cancer
|
Focke, Cornelia M.
|
|
2017
|
84 |
C |
p. 219-227
9 p.
|
artikel
|
| 18 |
Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors
|
Bandak, M.
|
|
2017
|
84 |
C |
p. 9-17
9 p.
|
artikel
|
| 19 |
Menopausal hormone therapy and cancer risk: An overestimated risk?
|
Simin, Johanna
|
|
2017
|
84 |
C |
p. 60-68
9 p.
|
artikel
|
| 20 |
Metformin targets gastric cancer stem cells
|
Courtois, Sarah
|
|
2017
|
84 |
C |
p. 193-201
9 p.
|
artikel
|
| 21 |
Nivolumab-associated nausea and vomiting as an immune adverse event
|
Shi, Yiwen
|
|
2017
|
84 |
C |
p. 367-369
3 p.
|
artikel
|
| 22 |
No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer
|
De La Pena, H.
|
|
2017
|
84 |
C |
p. 354-359
6 p.
|
artikel
|
| 23 |
Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer
|
Vassal, Gilles
|
|
2017
|
84 |
C |
p. 149-158
10 p.
|
artikel
|
| 24 |
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis
|
May-Wilson, Sebastian
|
|
2017
|
84 |
C |
p. 228-238
11 p.
|
artikel
|
| 25 |
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
|
Bigot, Frédéric
|
|
2017
|
84 |
C |
p. 212-218
7 p.
|
artikel
|
| 26 |
pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma
|
Schlitter, Anna Melissa
|
|
2017
|
84 |
C |
p. 121-129
9 p.
|
artikel
|
| 27 |
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
|
Marino, P.
|
|
2017
|
84 |
C |
p. 27-33
7 p.
|
artikel
|
| 28 |
Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study
|
Minicozzi, Pamela
|
|
2017
|
84 |
C |
p. 335-353
19 p.
|
artikel
|
| 29 |
Radiotherapy access in Belgium: How far are we from evidence-based utilisation?
|
Lievens, Y.
|
|
2017
|
84 |
C |
p. 102-113
12 p.
|
artikel
|
| 30 |
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
|
Kümmel, Sherko
|
|
2017
|
84 |
C |
p. 1-8
8 p.
|
artikel
|
| 31 |
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers
|
Lee, Y.C.
|
|
2017
|
84 |
C |
p. 114-120
7 p.
|
artikel
|
| 32 |
Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: A population-based study
|
Zong, Xuchen
|
|
2017
|
84 |
C |
p. 173-183
11 p.
|
artikel
|
| 33 |
Sex differences in cancer risk and survival: A Swedish cohort study
|
Radkiewicz, Cecilia
|
|
2017
|
84 |
C |
p. 130-140
11 p.
|
artikel
|
| 34 |
Societal challenges of precision medicine: Bringing order to chaos
|
Salgado, Roberto
|
|
2017
|
84 |
C |
p. 325-334
10 p.
|
artikel
|
| 35 |
Survival for patients with rare haematologic malignancies: Changes in the early 21st century
|
Pulte, Dianne
|
|
2017
|
84 |
C |
p. 81-87
7 p.
|
artikel
|
| 36 |
Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery
|
Gaudy-Marqueste, C.
|
|
2017
|
84 |
C |
p. 44-54
11 p.
|
artikel
|
| 37 |
The changing diagnostic pathway for lung cancer patients in Shanghai, China
|
Jiang, Tao
|
|
2017
|
84 |
C |
p. 168-172
5 p.
|
artikel
|
| 38 |
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis
|
Petrelli, Fausto
|
|
2017
|
84 |
C |
p. 141-148
8 p.
|
artikel
|
| 39 |
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma
|
Constantinidou, Anastasia
|
|
2017
|
84 |
C |
p. 257-261
5 p.
|
artikel
|
| 40 |
Treatment of oesophageal cancer – Stressing the patient perspective
|
Lordick, Florian
|
|
2017
|
84 |
C |
p. 360-362
3 p.
|
artikel
|
| 41 |
Tumour radiosensitivity is associated with immune activation in solid tumours
|
Strom, Tobin
|
|
2017
|
84 |
C |
p. 304-314
11 p.
|
artikel
|
| 42 |
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
|
Stintzing, Sebastian
|
|
2017
|
84 |
C |
p. 69-80
12 p.
|
artikel
|
Tijdschrift beschrijving